Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


May 04, 2015 7:20 AM ET

Life Sciences Tools and Services

Company Overview of RainDance Technologies, Inc.

Company Overview

RainDance Technologies, Inc. develops genomic tools for non-invasive liquid biopsy applications for the research, early detection, and treatment of cancer, and other inherited and infectious diseases. It offers RainDrop, a digital polymerase chain reaction platform that generates picoliter-sized droplets for multiplex detection of HIV, DNA, or RNA; and consumables, such as source chips and sense chips, and oil surfactants. The company provides ThunderStorm, an automated next-generation sequencing (NGS) content enrichment solution that enables researchers to process various samples per day and generate quality data; ThunderBolts, a NGS panel for profiling important cancer mutations; ThunderBo...

749 Middlesex Turnpike

Billerica, MA 01821

United States

Founded in 2004

104 Employees

Phone:

978-495-3300

Fax:

978-528-6090

Key Executives for RainDance Technologies, Inc.

Chief Executive Officer, President and Director
Age: 37
Co-Founder and Chief Technology Officer
Age: 45
Co-Founder
Chief Financial Officer
Age: 60
Compensation as of Fiscal Year 2014.

RainDance Technologies, Inc. Key Developments

RainDance Technologies, Inc. Announces Global Availability of the Thunderbolts Myeloid Panel

RainDance Technologies, Inc. announced global availability of the ThunderBolts Myeloid Panel, a next-generation sequencing (NGS) research assay designed to rapidly detect and cost-effectively analyze genetic mutations associated with AML (Acute Myeloid Leukemia), MDS (Myelodysplastic Syndromes), MPN (Myeloproliferative Neoplasms) and other myeloid cancer research. The research assay was developed with the RainDanceHemOnc Consortium, a select group of hematologic oncology experts drawn from prominent academic and cancer research centers in the U.S. and Europe. HemOnc Consortium members will present the latest performance data from the new panel during the American Association for Cancer Research (AACR) Annual Meeting in Philadelphia on April 18-22, 2015. The ThunderBolts Myeloid Panel is a pre-validated NGS assay for researching mutations and hotspots in 49 important genes implicated in the causation, prognosis and recurrence of certain blood and bone marrow cancers. The panel features NGS breakthroughs in low sample input (10 ng), high sequencing coverage (100 percent), uniformity (greater than 95 percent), and time-to-result (2.5 days). Scientists are using the ThunderBolts Myeloid Panel to profile mutations that can then be independently validated and monitored with the ultra-sensitive RainDrop® Digital PCR System, all based on a unified and single droplet technology platform. The HemOnc Consortium is continuing to work with RainDance to conduct research into a proprietary digital PCR portfolio of cell-free mutation assays to study and monitor the status of important genes in blood-based cancer progression and relapse.

RainDance Technologies, Inc. Announces Agreements with BioTech-Europe, Diatech Pharmacogenetics Srl, Labgene Scientific, and Neo-Science & Group to Distribute RainDance Products

RainDance Technologies, Inc. announced agreements with BioTech-Europe, Diatech Pharmacogenetics srl, Labgene Scientific, and Neo-Science & Group, enabling these companies to distribute RainDance products in Central and Eastern Europe, Italy, Switzerland, the Kingdom of Bahrain, State of Kuwait, Sultanate of Oman, State of Qatar, Kingdom of Saudi Arabia, and State of the United Arab Emirates. These agreements are the latest components of RainDance’s channel and expansion strategy to meet the growing demand for liquid biopsy applications outside the United States. RainDance Technologies offers an innovative product portfolio to research cell-free and cell-based biomarkers for hereditary risk predisposition, pathology and progression, and residual disease monitoring. The company’s research use only products include: RainDrop Digital PCR System: Ultra-sensitive digital PCR system for research of early detection and monitoring of cell-free and cell-based biomarkers for cancers, viruses, pathogens, and immune disorders. ThunderBolts NGS Enrichment System: New Democratized targeted NGS system enabling highly sensitive, rapid, low input, profiling of solid tumors and hematological cancer research in plasma, tissue and FFPE samples. ThunderStorm NGS Enrichment System: Industrial-scale workhorse for highly accurate, fully-automated targeted NGS enrichment.

RainDance Technologies, Inc. Announces the Launch and Availability of the ThunderBolts Next-Generation Sequencing Target Enrichment System

RainDance Technologies, Inc. announced the launch and availability of the ThunderBolts Next-Generation Sequencing (NGS) Target Enrichment System. The ThunderBolts System enables researchers to rapidly detect and cost-effectively analyze somatic mutations from liquid biopsy samples (circulating tumor DNA) or precious FFPE (formalin-fixed Paraffin-Embedded) tissue samples. RainDance recently showcased the new ThunderBolts System and performance data at the International Molecular Medicine Tri-Conference, and will highlight the ThunderBolts System at the upcoming Advances in Genome Biology and Technology Meeting. The ThunderBolts System is a fast, accurate and low-cost NGS target enrichment system that features award-winning instrumentation and pre-validated gene panels for profiling solid tumors and hematological cancers, as well as flexible `open source' options for the generation of custom gene panels. The ThunderBolts System features the streamlined RainDance DirectSeq primer design and amplification method, which eliminates library preparation steps, minimizes off-target sequencing, and triples the sample capacity per sequencing run, resulting in significant throughput, batching, turnaround time, and cost advantages. The ThunderBolts System provides researchers the ability to confidently detect somatic or hematologic tumor mutations with frequencies as low as 1%, starting with as little as 10 ng of amplifiable DNA., Scientists can use the ThunderBolts System to research and screen for low-frequency mutations and then orthogonally validate and track these mutations with the ultrasensitive RainDrop® Digital PCR System, as they utilize the same core droplet technology platform. In addition, all current RainDrop systems are enabled to run ThunderBolts NGS panels to further extend their versatility and value. The RainDrop and ThunderBolts Systems are research-use-only tools.

Similar Private Companies By Industry

Company Name Region
WCCT Global, LLC United States
SRU Biosystems, Inc. United States
IndiPharm, Inc. United States
MRC Beriatric Services Inc. United States
Boston Biomedical Associates LLC United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Greater Houston Partnership United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact RainDance Technologies, Inc., please visit raindancetech.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.